ArticleJAMA network open2024
Severe Pediatric Neurological Manifestations With SARS-CoV-2 or MIS-C Hospitalization and New Morbidity.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of race, ethnicity, and pediatric long COVID and MIS-C: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Delirium in Children Hospitalized with Acute COVID-19 or MIS-C: Secondary Analysis of the 2020-2021 Global Consortium Study of Neurologic Dysfunction in COVID-19.Neurocritical care · 2026Observational
- Neurological and Neuropsychiatric Manifestations of Pediatric Inflammatory Multisystem Syndrome (PIMS/MIS-C): A Narrative Review.Journal of personalized medicine · 2026Review
- Neurological and neurodevelopmental effects of Covid and MIS-C on children.Pediatric research · 2026Review
- Comment on "Prevalence and risk factors of paediatric seizures in COVID-19 infection: A study from Thailand".eNeurologicalSci · 2026Article
- Outcome of and Risk Factors for Mortality in Pediatric Coronavirus Disease 2019 Encephalitis During the 2022 Omicron Wave in Taiwan: A National Retrospective Study.Open forum infectious diseases · 2026Article
- MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026Review
- Prevalence and risk factors of pediatric seizures in COVID-19 infection: A study from Thailand.eNeurologicalSci · 2025Article
- Longitudinal functional and neuropsychological 2-year follow-up after intensive care admission for multisystem inflammatory syndrome in children.European journal of pediatrics · 2025Article
- Neurologic and Psychological Outcomes 2 Years After Multisystem Inflammatory Syndrome in Children.JAMA network open · 2025Article
- An Update on Multi-System Inflammatory Syndrome in Children.Current rheumatology reports · 2025Review
- Six clinical phenotypes with prognostic implications were identified by unsupervised machine learning in children and adolescents with SARS-CoV-2 infection: results from a German nationwide registry.Respiratory research · 2024Article
- Byline Errors.JAMA network open · 2024Article
Corrections and comments
- Commented on by
- Erratum issuedByline Errors.2024
Authors and funding
79 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Neurological manifestations during acute SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C) are common in hospitalized patients younger than 18 years and may increase risk of new neurocognitive or functional morbidity. Objective: To assess the association of severe neurological manifestations during a SARS-CoV-2-related hospital admission with new neurocognitive or functional morbidities at discharge. Design, Setting, and Participants: This prospective cohort study from 46 centers in 10 countries included patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C between January 2, 2020, and July 31, 2021. Exposure: Severe neurological manifestations, which included acute encephalopathy, seizures or status epilepticus, meningitis or encephalitis, sympathetic storming or dysautonomia, cardiac arrest, coma, delirium, and stroke. Main Outcomes and Measures: The primary outcome was new neurocognitive (based on the Pediatric Cerebral Performance Category scale) and/or functional (based on the Functional Status Scale) morbidity at hospital discharge. Multivariable logistic regression analyses were performed to examine the association of severe neurological manifestations with new morbidity in each SARS-CoV-2-related condition. Results: Overall, 3568 patients younger than 18 years (median age, 8 years [IQR, 1-14 years]; 54.3% male) were included in this study. Most (2980 [83.5%]) had acute SARS-CoV-2; the remainder (588 [16.5%]) had MIS-C. Among the patients with acute SARS-CoV-2, 536 (18.0%) had a severe neurological manifestation during hospitalization, as did 146 patients with MIS-C (24.8%). Among survivors with acute SARS-CoV-2, those with severe neurological manifestations were more likely to have new neurocognitive or functional morbidity at hospital discharge compared with those without severe neurological manifestations (27.7% [n = 142] vs 14.6% [n = 356]; P < .001). For survivors with MIS-C, 28.0% (n = 39) with severe neurological manifestations had new neurocognitive and/or functional morbidity at hospital discharge compared with 15.5% (n = 68) of those without severe neurological manifestations (P = .002). When adjusting for risk factors in those with severe neurological manifestations, both patients with acute SARS-CoV-2 (odds ratio, 1.85 [95% CI, 1.27-2.70]; P = .001) and those with MIS-C (odds ratio, 2.18 [95% CI, 1.22-3.89]; P = .009) had higher odds of having new neurocognitive and/or functional morbidity at hospital discharge. Conclusions and Relevance: The results of this study suggest that children and adolescents with acute SARS-CoV-2 or MIS-C and severe neurological manifestations may be at high risk for long-term impairment and may benefit from screening and early intervention to assist recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.